Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01554280




Registration number
NCT01554280
Ethics application status
Date submitted
11/03/2012
Date registered
14/03/2012
Date last updated
23/03/2021

Titles & IDs
Public title
Fully Coated, Removable, Self-expanding Oesophageal Stents for Preventing Strictures Following Complete Barretts Excision.
Scientific title
Fully, Coated, Removable, Self-expanding Oesophageal Stents for the Prevention of Oesophageal Stricture Following Endoscopic Mucosal Resection of Short Segment Barrett's With High Grade Dysplasia and Early Cancer.
Secondary ID [1] 0 0
CBE-001-SEOS
Universal Trial Number (UTN)
Trial acronym
CBE-001-SEOS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Constriction, Pathological 0 0
Condition category
Condition code
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Fully coated, removable , self-expanding oesophageal stent

Experimental: Oesophageal Stents - Patients enrolled will receive a fully coated, removable, self-expanding oesophageal stent.


Treatment: Devices: Fully coated, removable , self-expanding oesophageal stent
Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Improvement in Stricture Formation
Timepoint [1] 0 0
12 weeks

Eligibility
Key inclusion criteria
- Patients with short segment Barrett's Oesophagus with high grade dysplasia or early
cancer, having circumferential EMR to achieve complete Barrett's excision.

- Aged 18-75 years old

- Biopsy proven to be Barretts with HGD or EAC

- The absence or lymph node involvement

- Short segment <3cm of Barretts Oesophagus.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Women who are pregnant and the human foetus

- Children and/or young people <18 years

- People with an intellectual or mental impairment.

Study design
Purpose of the study
Prevention
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2014
Sample size
Target
Accrual to date
Final
12
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
2145 - Westmead

Funding & Sponsors
Primary sponsor type
Other
Name
Professor Michael Bourke
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to investigate whether preventative placement of a removable
oesophageal stent reduces the rate of scar tissue, or stricture formation after removing the
precancerous or early cancerous Barrett's mucosa by Endoscopic Mucosal Resection (EMR). The
stent will be placed 10-14 days after initial EMR. The stent will then be removed 8 weeks
later by repeat Endoscopy. Patients will be followed up weekly following insertion of the
oesophageal stent.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01554280
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Michael Bourke, MBBS
Address 0 0
WSLHD
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01554280